Immuneering Corporation Class A Common Stock (IMRX)

PHARMACEUTICAL PREPARATIONS

Immuneering Corporation Class A Common Stock (IMRX) is listed on Nasdaq, where it has traded since July 30, 2021.

Listed On
Nasdaq
Listed Since
July 30, 2021
Employees
57
Market Cap
$276M

About Immuneering Corporation Class A Common Stock

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 108 institutions reported holding IMRX, with 34.3 million shares worth $170.9 million in aggregate. The largest reported holder was FMR, with 9.7 million shares worth $48.4 million. Of the 5 largest holders listed below, 4 added shares and 1 held its position unchanged during the quarter.

InstitutionSharesValueQuarter change
FMR9,704,610$48MAdded 0.07%
BlackRock4,374,020$22MAdded 190.2%
Vanguard3,030,526$15MAdded 15.03%
Sanofi2,708,559$14MUnchanged
T. Rowe Price1,936,076$10MAdded 5.84%

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is IMRX?

Immuneering Corporation Class A Common Stock (IMRX) is listed on Nasdaq, where it has traded since July 30, 2021.

Who are the largest institutional holders of IMRX?

In 13F filings for the quarter ended June 30, 2026, the largest reported holders of IMRX were FMR, BlackRock and Vanguard.

How many institutions own IMRX?

108 institutions reported a position in IMRX for the quarter ended June 30, 2026, worth $170.9 million in total.

Did institutions buy or sell IMRX last quarter?

Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for IMRX.

Every reported institutional holder, plus insider and congressional trades in IMRX, on SentiSense.